Implementation of Basal–Bolus Therapy in Type 2 Diabetes: A Randomized Controlled Trial Comparing Bolus Insulin Delivery Using an Insulin Patch with an Insulin Pen
Richard M. Bergenstal(HealthPartners), Lyle Myers(California Institute for Biomedical Research), Bruce W. Bode(Emory University), Vanita R. Aroda(Brigham and Women's Hospital), Christopher T. Kelly(California Institute for Biomedical Research), Brian Levy(Unknown), Klaus Busch(California Institute for Biomedical Research), David Huffman(California Institute for Biomedical Research), Derek Muse(Jean Brown Research), Vivien Zraick(Johnson & Johnson (Brazil)), Anuj Bhargava(Iowa Diabetes and Endocrinology Research Center), Ronald Brazg(Rainier Clinical Research Center), Bogdan Catargi(California Institute for Biomedical Research), Tira Chaicha-Brom(California Institute for Biomedical Research), Andrew Collier(California Institute for Biomedical Research), H. Bihan(California Institute for Biomedical Research), Julio Rosenstock(Velocity Clinical Research (United States)), Sudesna Chatterjee(California Institute for Biomedical Research), Anne Farret(Centre National de la Recherche Scientifique), Rory J. McCrimmon(University of Dundee), Thomas Behnke(California Institute for Biomedical Research), Robert Lipetz(California Institute for Biomedical Research), M Hanefeld(Technische Universität Dresden), Timothy S. Bailey(Eli Lilly (United States)), Mark Kipnes(Diabetes & Glandular Disease Clinic), See Kwok(University of London), Mark E. Molitch(Christian Doppler Laboratory for Thermoelectricity), Pierre Sérusclat, Todd Gress(Edwards Comprehensive Cancer Center), John McKnight(California Institute for Biomedical Research), Davida Kruger(Henry Ford Health System), Leon Fogelfeld(California Institute for Biomedical Research), Mark Peyrot(Loyola University Maryland), Priscilla Hollander, Ruth S. Weinstock(SUNY Upstate Medical University), Juan P. Frías(University of Alabama at Birmingham), David C. Klonoff(Mills Peninsula Health Services), Sylvaine Clavel(California Institute for Biomedical Research), Richard A. Bernstein(Northwestern University), Mary L. Johnson(HealthPartners), Faramarz Beigi(California Institute for Biomedical Research), Steven B. Leichter(California Institute for Biomedical Research), David M. Shearer(Johnson & Johnson (Brazil)), Darlene M. Dreon(California Institute for Biomedical Research), Ramachandra G. Naik, Marc Lévy(California Institute for Biomedical Research), Shenaz Ramtoola(East Lancashire Hospitals NHS Trust), Belinda P. Childs(California Institute for Biomedical Research), Bertrand Cariou(Institut du Thorax)
Cited by 36
Related Papers
Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range
|Diabetes Care|2019|3.8k
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
|The Lancet|2019|3.1k
2. Classification and Diagnosis of Diabetes:<i>Standards of Care in Diabetes—2023</i>
|Diabetes Care|2022|2.4k
Cryptogenic Stroke and Underlying Atrial Fibrillation
|New England Journal of Medicine|2014|2.2k
International Consensus on Use of Continuous Glucose Monitoring
|Diabetes Care|2017|2k